Childhood asthma outcomes during the COVID-19 pandemic: Findings from the PeARL multi-national cohort - Papadopoulos, Nikolaos G.; Mathioudakis, Alexander G.; Custovic, Adnan; Deschildre, Antoine; Phipatanakul, Wanda; Wong, Gary; Xepapadaki, Paraskevi; Abou-Taam, Rola; Agache, Ioana; Castro-Rodriguez, Jose A.; Chen, Zhimin; Cros, Pierrick; et al. (medRxiv, 2020)
Importance Importance: The interplay between COVID-19 pandemic and asthma in children is still unclear.Objective We evaluated the impact of COVID-19 pandemic on childhood asthma outcomes.Design The PeARL multinational cohort included children with asthma and non-asthmatic controls recruited during the COVID-19 pandemic and compared current disease activity with data available from the previous year.Setting Pediatric outpatient clinics.Participants The study included 1,054 children with asthma and 505 non-asthmatic controls, aged between 4-18 years, from 25 pediatric departments, from 15 countries globally.Exposures COVID-19 pandemic first wave, starting from the date of the first fatality in the respective country.Main outcomes and measures We assessed the pandemic’s impact on the frequency of respiratory infections, emergency presentations and hospital admissions in asthmatic versus non-asthmatic participants, controlling for confounding factors including the pandemic’s duration and the frequency of such acute events during 2019. Using paired analyses, we evaluated the impact of the pandemic on the annualized frequency of asthma attacks and the previously mentioned acute events, asthma control, and pulmonary function in children with asthma, compared to their baseline disease activity, during the preceding year.Results During the pandemic, children with asthma experienced fewer upper respiratory tract infections, episodes of pyrexia, emergency visits, hospital admissions, asthma attacks and hospitalizations due to asthma, in comparison to the preceding year. Sixty-six percent of asthmatic children had improved asthma control while in 33% the improvement exceeded the minimally clinically important difference. Pre-bronchodilatation FEV1 and peak expiratory flow rate were also improved during the pandemic.When compared to non-asthmatic controls, children with asthma were not found to be at increased risk of LRTIs, episodes of pyrexia, emergency visits or hospitalizations during the pandemic. However, an increased risk of URTIs emerged.Conclusions and relevance Childhood asthma outcomes, including control, were improved during the first wave of the COVID-19 pandemic, probably because of reduced exposure to asthma triggers and increased treatment adherence. The decreased frequency of acute episodes does not support the notion that childhood asthma may be a risk factor for COVID-19. Furthermore, the potential for improving childhood asthma outcomes through environmental control becomes apparent.Question What was the impact of COVID-19 pandemic on childhood asthma outcomes?Findings During the first wave of the pandemic, children with asthma have experienced improved outcomes, as evidenced by fewer asthma attachks, hospitalizations, improved scores in validated asthma control measures and improved pulmonary function.Meaning This is the first study to show a positive impact of COVID-19 pandemic on childhood asthma activity. This is probably the result of reduced exposure to asthma triggers and increased treatment adherence. The decreased frequency of acute episodes does not support the hypothesis that childhood asthma may be a risk factor for COVID-19.Competing Interest StatementTJ reports grants from The Paulo Foundation, Helsinki, Finland. MT reports grants from The Sigrid Juselius Foundation, Helsinki, Finland, during the conduct of the study. None of the other authors had any conflicts of interest directly related to this work. AND, AF, KN, EH, LN-B, WP, ZC, WF, GW, LG-M, ZAW-S, YRHV, CFPB, DRY, CS, PLR, PS, RA-T, J-CD, JL, TR, DY, AMR, KW, RE-O, JAC-R, AG, CM, AILG, MM-A, EMNR, MKN, VF do not declare any conflicts of interest outside the submitted work either. NGP reports personal fees from ALK, Novartis, Nutricia, HAL, Menarini/FAES Farma, Sanofi, Mylan/MEDA, Biomay, AstraZeneca, GSK, MSD, ASIT BIOTECH and Boehringer Ingelheim; grants from Gerolymatos International SA and Capricare outside the submitted work. AGM reports grants from Boehringer Ingelheim outside the submitted work. AC reports personal fees from Novartis, Thermo Fisher Scientific, Philips, Sanofi, Stallergenes Greer, AstraZeneca, outside the submitted work. AD reports personal fees and other from Novartis, ALK, MYLAN, GSK, CHIESI, Astra Zeneca, DBV technologies, grants and personal fees from Stallergenes Greer, personal fees from AImmune, Zambon, Boehringer Ingelheim, Nestle HealthScience, other from Nutricia, outside the submitted work. IA reports and Associate Editor Allergy journal. PX reports personal fees from Nutricia, Nestle, Friesland, Uriach, Novartis Pharma AG, and GlaxoSmithkline outside the submitted work. CM reports personal fees from Novartis, GSK, ThermoFisher, Boehringer Ingelheim, outside the submitted workFunding StatementThis study was supported by the Respiratory Effectiveness Group (REG). REG has received support from AstraZeneca, Novartis and Sanofi for continued work on PeARL.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics review board, General Pediatric Hospital "Panagiotis & Aglaia Kyriakou", Athens, Greece. Athens 24-06-2020 Reference number: 11814. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDeidentified patient level data will be available upon request between 3 months and 5 years after the publication of this manuscript.